<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947957</url>
  </required_header>
  <id_info>
    <org_study_id>BEACH (29BRC19.0065)</org_study_id>
    <nct_id>NCT03947957</nct_id>
  </id_info>
  <brief_title>Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis</brief_title>
  <acronym>BEACH</acronym>
  <official_title>Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the predictive nature of the biomarker
      Porphyromonas catoniae measured at the age of 12 months in the occurrence of colonization
      with Pseudomonas aeruginosa at 24 months of age in children with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric study in 3 phases:

        -  Pre-inclusion: at the first visit to the CRCM (support for a positive screening
           confirmed by sweat test and genotyping CFTR)

        -  Inclusion: possible between the 2nd visit to the CRCM (about 2 months old) and the 6th
           month

        -  Follow-up: up to 24 months old. The pace of visits will be based on the usual follow-up
           rate of CF infants

      The clinical data as well as samples (expectorations, stools) will be collected on a monthly
      basis up to 6 months old and then every 2 months until one year old and finally quarterly
      until 2 years old.

        -  Tracheo-bronchial secretions will be collected at the CRCM

        -  Stools samples will be carried out by the parents prior to consultation with the CRCM

        -  A blood collection will be carried out annually in an annual report.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Infants will be included between the 2nd visit to the CRCM (about 2 months of age) and the 6th month then they will be followed until the age of 24 months. The pace of visits will be based on the usual follow-up rate of CF infants.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of P. aeruginosa in bacterial sputum cultures collected at 24 months of age</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute amount of P. aeruginosa at different sampling times.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute amount of P. catoniae in respiratory secretions at different sampling times and Delta between 12 and 24 months.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute amount of P. catoniae in stool at different sampling times and Delta between 12 and 24 months.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of dysbiosis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>collection of expectoration, stools and blood</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>collection of expectoration, stools and blood</intervention_name>
    <description>collection of expectoration, stools and blood</description>
    <arm_group_label>collection of expectoration, stools and blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Infants aged 6 months maximum at inclusion with a confirmed diagnosis of cystic
             fibrosis in its classical form (positive sweat test and/or two mutations of the CFTR
             gene from class I to III)

          -  Children free from any antecedent of colonization to P. aeruginosa at the time of
             inclusion (certified by the microbiological history supplemented by a molecular test
             by qPCR according to the diagram of Le gal et al., 2013)-Affiliation to the social
             security system

          -  Consent signed by the holders of parental authority or the sole parent holding
             parental authority / and &quot;oral&quot; agreement of the second holder

        Exclusion criteria:

          -  Severe acute pathology (other than cystic fibrosis) in progress, or requiring surgery

          -  Patient unable to undergo the tests required for the Protocol

          -  Patient whose parent (s) is (are) minor (s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve HERY-ARNAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve HERY-ARNAUD, Pr</last_name>
    <phone>+33 2 98 14 51 02</phone>
    <email>genevieve.hery-arnaud@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Francoise TROUSSIER, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Francosie TROUSSIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphanie BUI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle PIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe REIX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiphaine BIHOUEE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Tiphaine BIHOUEE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle SERMET-GAUDELUS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Harriet CORVOL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric DENEUVILLE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Eric DENEUVILLE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles RAULT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Gilles RAULT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe MARGUET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure COSSON, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Laure COSSON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending fifteen years following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

